Back to homepage

Haematology and Oncology

One-year prevalence, comorbidities and cost of cachexia-related inpatient admissions in the USA

Authors: Susan T Arthur, Joshua M Noone, Bryce A Van Doren, Debosoree Roy, Christopher M Blanchette

Cachexia is a condition characterized as a loss in body mass or metabolic dysfunction and it is associated with several prevalent chronic health conditions including many cancers, COPD, HIV, and kidney disease. Currently there is little research into cachexia and the objective of this article is to characterize cachexia patients, their healthcare utilisation, and associated hospitalization costs.


A new health-related quality of life instrument for leukemia: will it be widely adopted soon?

Authors: Junhua Yu, Joanna Cheung

Over the last decade, an increasing number of clinical trials in cancer research have been incorporating a health-related quality of life (HRQoL) instrument as part of their trial design. In this article the authors discuss the validity and usefulness of a new HRQoL instrument already in use in the United States.


Targeting the metabolism of leukemia stem cells as a novel therapeutic strategy

Authors: Emmanuel A Ho, Neal M Davies

Unraveling our understanding of cancer stem cells and their role in the development and progression of acute myeloid leukemia could lead to improved outcomes.


Novel therapeutic modalities and drug delivery in pancreatic cancer – an ongoing search for improved efficacy

Authors: Yuqing Zhang, Kei Satoh and Min Li

Pancreatic cancer is a challenging disease due to its high rates of resistance to traditional chemotherapy and radiotherapy. There has been little improvement in the prognosis of pancreatic cancer cases in the past decades, highlighting the need for more effective therapeutic approaches. This article summarizes current developments in targeted pancreatic cancer drug delivery, focusing on delivery systems, targets, and therapeutic agents.


Metastatic melanoma – a review of current and future drugs

Authors: Tiago Rodrigues Velho

A systematic search of literature was conducted, and studies providing data on the effectiveness of current and/or future drugs used in the treatment of metastatic melanoma were selected for review. This review discusses the advantages and limitations of these agents, evaluating past, current and future clinical trials designed to overcome such limitations.